Immix Biopharma (NASDAQ:IMMX) Rating Increased to Hold at Wall Street Zen

Immix Biopharma (NASDAQ:IMMX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Immix Biopharma Stock Performance

Shares of IMMX stock opened at $5.83 on Friday. The stock has a market capitalization of $308.76 million, a price-to-earnings ratio of -7.57 and a beta of 0.31. Immix Biopharma has a one year low of $1.34 and a one year high of $7.73. The company’s 50-day simple moving average is $5.30 and its 200-day simple moving average is $3.60.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.05). As a group, research analysts forecast that Immix Biopharma will post -0.87 EPS for the current year.

Hedge Funds Weigh In On Immix Biopharma

Several institutional investors have recently modified their holdings of IMMX. Citadel Advisors LLC acquired a new stake in Immix Biopharma in the 3rd quarter valued at approximately $188,000. United Capital Financial Advisors LLC bought a new position in shares of Immix Biopharma in the third quarter worth $148,000. Imprint Wealth LLC acquired a new position in shares of Immix Biopharma during the third quarter valued at $141,000. Susquehanna International Group LLP raised its stake in shares of Immix Biopharma by 78.8% during the third quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock valued at $190,000 after purchasing an additional 40,032 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Immix Biopharma by 4.5% in the third quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock worth $1,526,000 after purchasing an additional 31,625 shares during the period. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.